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155 Isolation of fungi from nebuliser devices used by people with
cystic ﬁbrosis
D. Peckham1, S. Wynne1, M. Denton2, K. Pollard1, R. Barton3. 1Adult Cystic
Fibrosis Unit, St James’s University Hospital, Leeds, United Kingdom; 2Department
of Microbiology, Leeds General Inﬁrmary, Leeds, United Kingdom; 3Mycology
Reference Centre, Leeds General Inﬁrmary, Leeds, United Kingdom
Objectives: Nebulised therapy plays a major role in the treatment of CF. Maintain-
ing nebuliser hygiene is time consuming and if inadequate can result in fungal
contamination. The aim of this study was to assess the prevalence of fungal
contamination in nebuliser devices.
Methods: Adult patients were prospectively recruited. Nebulisers were sampled
using wet sterile swabs. Samples including controls were plated out on Sabouraud
agar and on Scel+ agar to select for Scedosporium sp. and incubated at 27ºC for up
to 2 weeks. Yeasts were identiﬁed by germ tube test, Auxacolour, or MALDI-TOF
examination. Moulds were identiﬁed by microscopy, or examination of rRNA gene
and spacer sequence.
A total of 275 devices/i-neb chambers from 149 subjects were swabbed. In addition
swabs were taken from the horn of 94 i-neb devices. Fungal cultures were positive
in one or more devices from 86 (57.7%) patients. In 39/149 (26.2%) of study
subjects yeasts were isolated, in 47/149 (31.5%) moulds and 20/149 (13.4%) yeasts
and moulds. Contamination was not associated with any particular medication and
there was no signiﬁcant difference between the contamination rate of and different
devices. Aspergillus sp. were isolated from 28 (10.4%) devices, Scedosporium sp.
were not isolated from any devices. There was no obvious correlation between
positive culture from devices and previous sputum specimens.
Conclusion: Nebuliser devices are frequently contaminated by moulds and yeasts,
resulting in a potential vehicle for infection. More emphasis should be placed on
ensuring adequate nebuliser hygiene and the development of disposable devices.
Supported by an educational grant from Novartis.
156 Chronic airway colonization by Aspergillus fumigatus (Af) in
patients with cystic ﬁbrosis (CF): Does it contribute to lung
function decline?
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Background: In vitro studies showed that Af can produce a bioﬁlm on CF bronchial
epithelial cells. In the absence of allergic bronchopulmonary aspergillosis (ABPA),
the impact of persistence of Af in the airways on the course of lung disease remains
unclear.
Objectives: To assess clinical characteristics and FEV1 decline in patients with CF
and chronic airway colonization by Af compared to control subjects.
Methods: 179 children and adults with CF with at least 3 sputum cultures/year
in the last 4 years were considered. Chronic airway colonization was deﬁned as
the presence of more than 50% of positive cultures for Af in two consecutive
years (Group A). For each case two control subjects were matched for sex, age,
mean value of FEV1 and presence/absence of P. aeruginosa in sputum cultures
(Group B). Individual decline in FEV1 during the last 4 years was evaluated using
llinear regression analysis.
Results: 14/179 (8%) of patients had chronic airway colonization by Af. Patients in
Group A had a median (IQR) age of 23.9 (20.5, 44.5) years; only one patient fulﬁll
criteria for ABPA and 7/14 patients had concomitant chronic airway infection by
P. aeruginosa. The median value of FEV1 in the last 2 years was 60 (35, 74) and
61 (44, 70) % predicted in Group A and B, respecitively. There was no difference
in the median value of FEV1 decline in the two groups [A: −0.46 (−2.61, 1.11) %
pred/yr; B: −1.72 (−3.37, −0.29) % pred./yr].
Conclusion: 8% of adults had chronic airway colonization by Af. It was not
associated with deterioration of lung function. To ascertain the role of Af a longer
period of chronic airway colonization should be prospectively evaluated.
157 Epidemiology of aspergillosis in CF and response to antifungal
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Objectives: Aspergillus sp., particularly A. fumigatus are frequently isolated from
respiratory samples from people with cystic ﬁbrosis (CF). The clinical signiﬁcance
of such isolates can be difﬁcult to determine. The aim of this study was to
determine risk factors for Aspergillus disease including allergic bronchopulmonary
aspergillosis (ABPA) and Aspergillus bronchitis (AB).
Method: The data from a cohort of 473 people (age over 16 years) was extracted
from the unit’s electronic patient management system (Egton Medical Information
Systems) between 2009 and 2011. We examined parameters including, age, height,
weight, lung function, C-reactive protein measurements, blood counts, fungal cul-
tures, Microbiology, symptomology, radiology, antibiotic therapy, steroid treatment,
and comorbitidies. Factors associated with ABPA and AB were identiﬁed by
multivariate logistic regression analysis.
Result: Factors associated with ABPA included eosinophilia and the presence of a
“tree-in-bud” sign on chest CT; factors associated with AB included isolation of
Rasamsonia argillacea or Scedosporium apiospermum, use of certain antibiotics
and raised white cell count. Ninety-seven patients were treated with mould-active
antifungals and responses categorised as positive response to treatment or treatment
failure.
Conclusion: Early results have identiﬁed speciﬁc factors associated with ABPA
and AB. Similar analysis of factors associated with positive response to treatment
is still being analysed and will be presented.
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Objectives: Trichosporon mycotoxinivorans has been reported as an emerging
pathogen in CF patients. Due to misidentiﬁcation by commercially available yeast
identiﬁcation systems it may be underdiagnosed as a Trichosporon species other
than Trichosporon mycotoxinivorans or even as Cryptococcus species.
Methods: Trichosporon isolates were identiﬁed phenotypically and by sequencing
of the internal transcribed spacer (ITS) regions of rDNA, in vitro susceptibility
testing was performed by CLSI methodology. Genotyping has been performed
by sequencing of the RNA polymerase II second largest subunit (RPB2) and the
intergenic spacer (IGS) region.
Results: Since 2009 ten patients between 12 and 30 yrs of age in Germany have
been identiﬁed to be colonized by Trichosporon mycotoxinivorans. Respiratory
function deteriorated in selected patients. All isolates of untreated patients were in
vitro susceptible to voriconazole, whilst those obtained during antifungal treatment
showed a rapid development of resistance to voriconazole, associated with a
prominent decrease of FEV1. The source of infection remains unclear. Genotyping
revealed a diverse genetic background among the isolates.
Conclusion: Trichosporon mycotoxinivorans is increasingly identiﬁed in CF pa-
tients and can be associated with worsening of the pulmonary function. Systemic
antifungal therapy seems to be limited by rapid development of in vitro resistance
under azole monotherapy.
